Relationship Between Right Ventricular Function and Chronotropic Incompetence in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease Authors: Yuki Nakamura, Michinari Hieda, Koshi Setoyama, Takeshi Someya, Nobuhito Nakanishi, Masashi Mitani, Taiki Makita, Keisuke Hidaka, Masahiro Takeo, Miyuki Nakahara, Hajime Miki, Yutaro Naka, Hiroki Okabe, Takeshi Onoue, Yasufumi Nagata, Mai Iwataki, Jun-ichiro Koga, Yasushi Oginosawa, Masaharu Kataoka Published: 2026 ABSTRACT AbstractBackgroundPulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) is a progressive disease characterized by remodeling of the pulmonary vasculature, leading to increased right ventricular (RV) afterload and impaired exercise capacity.Research QuestionThe impact of RV dysfunction on chronotropic response remains poorly understood in patients with CTD-PAH.Study Design and MethodsThis observational cohort study was conducted at our institution between April 2022 and March 2025. We enrolled 89 consecutive patients with CTD-PAH; 22 patients were excluded because of beta-blocker use (n = 9) or inability to exercise (n = 13). A total of 67 patients underwent echocardiography and exercise-stress right heart catheterization. Patients were classified into a preserved RV function group (tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure, ≥ 0.55; n = 47) and an impaired RV function group (tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure, < 0.55; n = 20); clinical parameters and outcomes were compared. Chronotropic incompetence was defined as peak heart rate (HR) < 85% of age-predicted HR and < 80% chronotropic response index: (maximum HR − resting HR)/(220 – age − resting HR).ResultsChronotropic incompetence affected 94% of patients. Age, sex, body size, BP, and left ventricular ejection fraction were comparable between the 2 groups. Compared with the preserved RV group, the impaired RV group had a lower chronotropic response index (preserved vs impaired RV group: 47.1% ± 20.3% vs 35.6% ± 14.8%; P = .034), lower delta HR/resting HR (0.56 ± 0.26 vs 0.36 ± 0.14; P = 0.003), lower mixed venous oxygen at rest (74.4% ± 3.7% vs 70.1% ± 7.0%; P = .004), lower peak oxygen consumption (517.1 ± 202.3 vs 402.2 ± 153.1 mL/min; P = .024), and higher peak pulmonary vascular resistance (2.2 ± 1.3 vs 3.5 ± 2.1 Wood units; P = .013).InterpretationChronotropic incompetence was observed in 94% of patients with CTD-PAH. RV dysfunction was associated with worse chronotropic response and contributed to reduced exercise capacity.Key Words: chronotropic incompetence, chronotropic response index, exercise-stress right heart catheterization, heart rate response, pulmonary arterial hypertension Take-Home Points Study Question: Although patients with pulmonary artery hypertension (PAH) are known to often exhibit chronotropic incompetence, does right ventricular impairment in patients with PAH associated with connective tissue disease (CTD) affect chronotropic incompetence? Results: Chronotropic response evaluated using the chronotropic response index and delta heart rate/resting heart rate was significantly lower in the tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure < 0.55 group. Interpretation: Chronotropic incompetence was highly prevalent in patients with PAH associated with CTD; patients with more severe PAH and concomitant right ventricular impairment were more likely to exhibit a worse chronotropic response, which further exacerbates exercise intolerance. Pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD) (CTD-PAH) is a progressive condition characterized by pulmonary vascular remodeling, leading to increased right ventricular (RV) afterload and impaired exercise capacity.1, 2, 3 Chronotropic incompetence has been reported as a limitation of cardiac output (CO) increase, and therefore, a factor of exercise intolerance and worse prognosis in cardiopulmonary disease.4 Previous studies have demonstrated that patients with PAH frequently exhibit chronotropic incompetence, defined as an inadequate increase in heart rate (HR) during exercise and impaired HR recovery after cessation of exercise.5, 6, 7 A blunted HR increase during the 6-minute walk test independently predicted exercise intolerance in patients with PAH,5,8 reduced HR recovery correlated with a higher New York Heart Association classification, and an elevated N-terminal pro-B-type natriuretic peptide level.7 These abnormalities in PAH reflect autonomic nervous system dysfunction and prognosis.9,10 Autonomic cardiovascular regulation, including HR response during exercise and HR recovery after exercise, provides additional prognostic and pathophysiological insights.5, 6, 7 Studies suggest that impaired HR recovery predicts all-cause mortality and exercise intolerance in patients with CTD-PAH.11 Additionally, patients with CTD-PAH frequently develop PAH and RV dysfunction, which significantly impact disease progression.12 At present, RV function adaptation for afterload is reported to determine symptoms or prognosis of PAH, known as RV-pulmonary arterial (PA) coupling. As a noninvasive marker of RV-PA uncoupling, the tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary arterial pressure (sPAP) ratio (TAPSE/sPAP) was reported to be useful.13 Although previous studies have demonstrated that patients with PAH frequently exhibit chronotropic incompetence, the specific relationship between RV dysfunction and this abnormal chronotropic response remains unclear. The role of RV dysfunction in the pathogenesis of chronotropic incompetence in CTD-PAH is poorly understood. Therefore, we hypothesized that impaired RV function was associated with the development of chronotropic incompetence in patients with CTD-PAH. To test this, this study investigated chronotropic incompetence in patients with CTD-PAH according to RV function using echocardiography and exercise right heart catheterization (RHC). Study Design and Methods Study Design and Population This single-center, observational, cohort study was conducted at the University of Occupational and Environmental Health, Japan, between April 2022 and March 2025. Consecutive adult patients diagnosed with CTD were included. PAH was diagnosed according to the current European Society of Cardiology/European Respiratory Society guidelines using RHC, demonstrating a mean pulmonary arterial pressure > 20 mm Hg, a pulmonary artery wedge pressure (PAWP) ≤ 15 mm Hg, and a pulmonary vascular resistance (PVR) > 2.0 Wood units (WU).14 Eligible patients were clinically stable, defined as no unexpected hospitalization, no change in targeted PAH therapy, and no acute decompensation within the preceding 3 months. The exclusion criteria included arrhythmia (sustained ventricular tachycardia, atrial fibrillation, or atrial flutter), pacemaker implantation, advanced left-sided heart disease, COPD with resting hypoxemia, and inability to perform exercise testing. Patients using beta-blockers were excluded because of direct interference with chronotropic response. Participants were divided into 2 groups based on TAPSE/sPAP: (1) preserved RV function (TAPSE/sPAP ≥ 0.55) and (2) impaired RV function (TAPSE/sPAP < 0.55).15 The study protocol was approved by the institutional review board of the University of Occupational and Environmental Health, Japan (No. UOEH-CRB22-026), and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki. Study Protocol All patients underwent exercise RHC. The exercise protocol was as follows: patients in a supine position performed a submaximal ergometric cardiopulmonary exercise test. After an RHC at rest, a 10-W workload was applied for 3 minutes, followed by a progressive workload of 10 W per minute. Maximum oxygen consumption (V˙o2) was collected using breath gas analysis during the exercise test. HR was recorded at baseline, every 3 minutes during exercise, at peak exercise, and after exercise. HR response during exercise was evaluated using the chronotropic response index (CRI), calculated as follows: ([peak HR − resting HR]/[APHR − resting HR]) × 100, where APHR is age-predicted heart rate and defined as (220 − age) beats/min. Chronotropic incompetence was defined as < 85% of APHR and < 80% of the CRI.16 The delta HR to resting HR ratio ([peak HR − resting HR]/resting HR) was measured as a parameter of chronotropic response.17 Echocardiography was performed with patients in the supine position after at least 15 minutes of rest. Transthoracic echocardiography images were acquired by an experienced sonographer and reinterpreted by a cardiologist specializing in echocardiography. Left ventricular (LV) systolic and diastolic functions were assessed according to the guidelines of the American Society of Echocardiography and the European Association of Cardiovascular Imaging.18,19 Echocardiographic parameters were obtained as follows: LV size, LV wall width, LV ejection fraction, LV transmitral inflow, tricuspid annular velocity (RV s'), and inferior vena cava (IVC) diameter. LV systolic and diastolic volumes were calculated using the Teichholz method.20 Tricuspid regurgitation (TR) pressure gradient was estimated using the simplified Bernoulli equation and TR jet velocity. sPAP was calculated as the sum of the TR pressure gradient, and right atrial pressure was estimated by the IVC condition. RV dysfunction was defined as TAPSE/sPAP < 0.55 for a surrogate marker of RV-PA uncoupling.15 Right-Sided Catheterization at Rest/Exercise RHC was performed at rest and during exercise.21,22 Right atrial pressure, RV pressure, pulmonary arterial pressure (PAP), and PAWP were measured at end-expiration at baseline and peak exercise. Exercise RHC followed a treadmill protocol: 10 W for 3 minutes, and then a progressive workload of 10 W per minute. PAWP, PAP, saturation of arterial oxygen, saturation of mixed venous oxygen, and V˙o2 were measured at baseline and every 3 minutes during exercise. CO was calculated using the direct Fick method.23 Outcomes The primary outcomes were the prevalence of chronotropic incompetence and the severity of chronotropic response, evaluated by the CRI and delta HR/resting HR. The secondary outcomes included hemodynamic parameters (eg, BP, stroke volume [SV], CO, V˙o2). Echocardiography and RHC data were also compared between the preserved RV vs impaired RV function groups. Statistical Analysis Continuous variables were presented as mean ± SD for normally distributed data and median (Q1-Q3) for nonnormally distributed variables. Between-group comparisons were performed using an unpaired t test for normally distributed variables or Wilcoxon test for nonnormal variables. Categorical data were assessed using the Pearson χ2 test. P < .05 was considered statistically significant. All statistical analyses were conducted using JMP Pro Version 17.0 (JMP Statistical Discovery LLC, Cary, NC, USA). Results Patient Characteristics We reviewed 89 patients with CTD suspected of having PAH who were referred to the department of cardiology and underwent exercise RHC. Nine patients were excluded because they used beta-blockers, and 13 were unable to perform exercise (Fig 1). Ultimately, 67 patients were included in this study. Chronotropic incompetence was highly prevalent, affecting 94% of the patients (Fig 2A). The prevalence of chronotropic incompetence was comparable between the 2 groups (91.5% vs 100%; P = .086) (Fig 2B). Additionally, the percentage of patients with peak HR > 100 beats/min was comparable between the 2 groups (68.0% vs 65.0%; P = .806) (Fig 2C). Study design. Patients with pulmonary arterial hypertension associated with connective tissue disease underwent exercise right heart catheterization (N = 89). Beta-blocker usage (n = 9) and exercise intolerance (n = 13) were excluded. The remaining 67 patients were divided into 2 groups by right ventricular function: TAPSE/sPAP ≥ 0.55 or < 0.55. sPAP = systolic pulmonary arterial pressure; TAPSE = tricuspid annular plane systolic excursion. A-C, Prevalence of chronotropic incompetence. A, Chronotropic incompetence was observed in 94% (63/67) of patients with pulmonary arterial hypertension undergoing exercise right heart catheterization. B, The TAPSE/sPAP ≥ 0.55 group had a 91.5% chronotropic incompetence prevalence, and the TAPSE/sPAP < 0.55 group had a 100% prevalence (P = .086). C, Peak HR > 100 beats/min was observed in 68.0% of patients in the TAPSE/sPAP ≥ 0.55 vs 65.0% of patients in the TAPSE/sPAP < 0.55 group (P = .806). Chronotropic incompetence was defined as < 85% of age-predicted HR: (220 − age) beats/min, and < 80% of the chronotropic response index: (peak HR − resting HR)/(220 − age − resting HR) × 100. HR = heart rate; sPAP = systolic pulmonary arterial pressure; TAPSE = tricuspid annular plane systolic excursion. There were no significant differences in age, sex, body surface area, comorbidities (hypertension, diabetes, dyslipidemia, and hypothyroidism), hemoglobin, and N-terminal pro-B-type natriuretic peptide levels between the 2 groups. There were 4 patients (6.0%) with thyroid dysfunction, with all of them maintaining euthyroid for at least 1 year. Creatinine levels were higher, and corticosteroid use was more frequent in the TAPSE/sPAP < 0.55 group. The use of medications affecting HR other than beta-blockers, such as calcium channel blockers (dihydropyridine type only in this cohort) and angiotensin Ⅱ receptor blockers, was similar between the 2 groups. The types of pulmonary hypertension (PH) were as follows: 23 patients (34.3%) met the criteria for precapillary PH, and 34 patients (50.8%) were diagnosed with exercise PH. The underlying CTD subtype, specifically systemic sclerosis vs nonsystemic sclerosis, was comparable between the 2 groups (Table 1). The PAWP/CO slope > 2 mm Hg/L/min was met in 32 patients (47.8%). Table 1Baseline CharacteristicsCharacteristicAll (N = 67)TAPSE/sPAP≥ 0.55 (n = 47)TAPSE/sPAP< 0.55 (n = 20)Age, y68.0 (61.0-75.0)71.0 (63.0-76.0)66.5 (60.3-70.8)Sex, male9 (13.4)6 (12.8)3 (15.0)Body height, cm153.4 (149.0-158.0)153.0 (149.0-158.0)154.0 (148.3-155.8)Body weight, kg50.3 (44.5-56.2)50.5 (44.0-57.0)47.7 (44.7-54.5)Body surface area, m21.46 (1.36-1.59)1.48 (1.36-1.62)1.42 (1.37-1.56)Comorbidities Hypertension32 (47.8)24 (51.1)8 (40.0) Diabetes5 (7.5)3 (6.4)2 (10.0) Dyslipidemia21 (31.3)12 (25.5)9 (45.0) CKD25 (37.3)14 (29.8)11 (55.0) Thyroid dysfunction4 (6.0)3 (6.4)1 (5.0)Blood test Blood urea nitrogen, mg/dL16.0 (13.0-19.0)16.0 (13.0-19.0)17.0 (14.0-20.0) Creatinine, mg/dL0.72 (0.60-0.83)0.69 (0.58-0.80)0.81 (0.67-0.90) eGFR, mL/min/1.7 m265.6 (53.0-77.0)68.0 (54.0-79.0)58.5 (51.3-68.5) Hb, g/dL12.0 (11.1-13.0)12.2 (11.5-13.1)11.8 (11.1-12.8) NT-pro-BNP, pg/mL119.0 (76.5-221.5)118.0 (66.5-223.3)127.0 (112.0-220.0)Medications CCB22 (32.8)17 (36.2)5 (25.0) ARB20 (29.9)16 (34.0)4 (20.0) Corticosteroids15 (22.4)6 (12.8)9 (45.0)Type of PH Precapillary PH23 (34.3)13 (27.7)10 (50.0) Exercise PH34 (50.8)27 (57.5)7 (35.0) Other10 (14.9)7 (14.9)3 (15.0)Type of CTD-SSc39 (58.2)30 (63.8)9 (45.0)Data are presented as median (Q1-Q3) or No. (%). ARB = angiotensin Ⅱ receptor blocker; CCB = calcium channel blocker; CKD = chronic kidney disease; CTD = connective tissue disease; eGFR = estimated glomerular filtration rate; Hb = hemoglobin; NT-pro-BNP = N-terminal pro-brain natriuretic peptide; PH = pulmonary hypertension; sPAP = systolic pulmonary arterial pressure; SSc = systemic sclerosis; TAPSE = tricuspid annular plane systolic excursion. Baseline Characteristics Data are presented as median (Q1-Q3) or No. (%). ARB = angiotensin Ⅱ receptor blocker; CCB = calcium channel blocker; CKD = chronic kidney disease; CTD = connective tissue disease; eGFR = estimated glomerular filtration rate; Hb = hemoglobin; NT-pro-BNP = N-terminal pro-brain natriuretic peptide; PH = pulmonary hypertension; sPAP = systolic pulmonary arterial pressure; SSc = systemic sclerosis; TAPSE = tricuspid annular plane systolic excursion. Regarding echocardiographic parameters, there were no significant differences in BP, LV ejection fraction, LV wall thickness, E/e', and IVC diameters between the 2 groups at baseline (all P > 0.05) (Table 2). LV diastolic volume, stroke volume, and E wave were significantly higher in the TAPSE/sPAP ≥ 0.55 group (Table 2). Table 2Echocardiographic Data: Comparisons of the 2 Groups at RestAll (N = 67)TAPSE/sPAP≥ 0.55 (n = 47)TAPSE/sPAP < 0.55 (n = 20)P ValueLVDd, mm41.6 [4.9]42.8 [4.8]38.8 [4.1].006LVDs, mm24.9 [4.8]25.3 [5.4]24.1 [3.2].307IVS, mm9.0 [1.5]8.9 [1.6]9.0 [1.3].593PW, mm9.2 [1.4]9.2 [1.5]9.1 [1.2].891LVEF, %56.7 [3.7]56.8 [3.9]56.4 [3.1].932Stroke volume, mL56.2 [9.7]58.3 [9.0]51.3 [9.5].006IVC, mm9.9 [3.7]9.8 [3.8]9.9 [3.6].863LVEDV, mL78.3 [22.5]83.6 [23.2]66.1 [15.5].006LVEDVi, mL/m252.8 [12.4]55.7 [11.9]45.9 [11.1].004LVESV, mL23.6 [11.0]24.7 [12.2]21.1 [7.2].307LVESVi, mL/m215.9 [7.0]16.4 [7.4]14.8 [6.1].321E, cm/s64.6 [17.8]66.5 [14.8]60.2 [23.1].020A, cm/s82.2 [18.4]82.0 [18.7]82.6 [18.3].661E/A0.81 [0.32]0.85 [0.33]0.73 [0.28].038DcT, ms221.9 [59.7]224.4 [64.7]215.9 [47.1].661e', cm/s6.1 [2.2]6.2 [1.7]6.0 [3.1].212E/e'11.6 [4.6]11.8 [4.5]11.1 [4.8].464Systolic BP, mm Hg130.0 [21.8]132.3 [20.3]124.6 [24.7].183Diastolic BP, mm Hg74.5 [12.4]74.0 [13.0]75.6 [11.3].384TAPSE, mm20.3 [4.0]21.8 [3.2]16.6 [2.9]< .0001TRPG, mm Hg29.6 [10.6]26.2 [6.0]37.6 [14.3]< .0001TAPSE/sPAP0.64 [0.22]0.74 [0.18]0.41 [0.11]< .0001Right ventricular s', cm/s12.3 [2.6]12.5 [2.2]11.8 [3.3].242Data are presented as mean [SD] or as otherwise indicated. Items showing statistically significant differences are indicated in bold. DcT = deceleration time; IVC = inferior vena cava; IVS = interventricular septum; LVDd = left ventricular diastolic diameter; LVDs = left ventricular systolic diameter; LVEDV = left ventricular end-diastolic volume; LVEDVi = left ventricular end-diastolic volume index; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; LVESVi = left ventricular end-systolic volume index; PW = posterior wall; sPAP = systolic pulmonary arterial pressure; TAPSE = tricuspid annular plane systolic excursion; TRPG = tricuspid regurgitation pressure gradient. Echocardiographic Data: Comparisons of the 2 Groups at Rest Data are presented as mean [SD] or as otherwise indicated. Items showing statistically significant differences are indicated in bold. DcT = deceleration time; IVC = inferior vena cava; IVS = interventricular septum; LVDd = left ventricular diastolic diameter; LVDs = left ventricular systolic diameter; LVEDV = left ventricular end-diastolic volume; LVEDVi = left ventricular end-diastolic volume index; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; LVESVi = left ventricular end-systolic volume index; PW = posterior wall; sPAP = systolic pulmonary arterial pressure; TAPSE = tricuspid annular plane systolic excursion; TRPG = tricuspid regurgitation pressure gradient. Resting HR was higher in the TAPSE/sPAP < 0.55 group (70.0 ± 9.9 vs 75.9 ±10.6 beats/min; P = .037); otherwise, peak HR did not differ significantly (Table 3). The CRI was substantially lower in the TAPSE/sPAP < 0.55 group (47.1% ± 20.3% vs 35.6% ± 14.8%; P = .034) (Fig 3A). In addition, delta HR/resting HR was lower in the TAPSE/sPAP < 0.55 group (0.560 ± 0.261 vs 0.364 ± 0.142; P = .003) (Fig 3B). Table 3Exercise Right Heart Catheterization: Comparisons of HR Response and HemodynamicsAll (N = 67)TAPSE/sPAP≥ 0.55 (n = 47)TAPSE/sPAP < 0.55 (n = 20)P ValueHR rest, beats/min71.7 [10.4]70.0 [9.9]75.9 [10.6].037HR peak, beats/min106.6 [17.0]108.1 [17.7]103.2 [15.2].384APHR, %70.0 [11.4]71.3 [11.7]66.9 [10.3].247CRI, %43.7 [19.5]47.1 [20.3]35.6 [14.8].034ΔHR/resting HR0.502 [0.248]0.560 [0.261]0.364 [0.142].003Systolic BP rest, mm Hg145.1 [23.7]147.0 [23.8]140.7 [23.3].407Diastolic BP rest, mm Hg70.7 [14.4]70.0 [13.6]72.4 [16.4].962Mean BP rest, mm Hg95.5 [14.5]95.6 [13.3]95.1 [17.2].800RAP rest, mm Hg4.5 [2.2]4.6 [2.1]4.4 [2.3].497sPAP rest, mm Hg30.0 [8.5]28.7 [6.9]33.4 [11.1].159dPAP rest, mm Hg11.8 [4.9]10.8 [3.4]14.3 [6.9].094mPAP rest, mm Hg18.5 [5.6]17.2 [4.2]21.5 [7.1].015PAWP rest, mm Hg9.2 [3.3]9.4 [3.2]8.8 [3.6].370Stroke volume rest, mL65.2 [23.9]69.3 [23.1]55.5 [23.4].012CO rest, L/min4.6 [1.8]4.8 [1.7]4.2 [2.1].042Svo2 rest, %73.1 [5.3]74.4 [3.7]70.1 [7.0].004PVR rest, WU2.4 [1.7]1.9 [1.1]3.6 [2.3].001V˙O2 rest, mL/min164.0 [48.8]167.1 [52.5]156.8 [38.9].556Systolic BP peak, mm Hg191.3 [36.5]198.9 [35.4]173.7 [33.7].016Diastolic BP peak, mm Hg83.3 [16.0]85.2 [16.5]78.7 [14.2].170Mean BP peak, mm Hg119.3 [18.7]123.1 [17.4]110.3 [19.0].021mPAP peak, mm Hg32.8 [7.2]32.5 [7.8]33.7 [5.9].466PAWP peak, mm Hg16.2 [6.2]17.1 [6.2]14.2 [5.7].068Stroke volume peak, mL69.8 [25.7]72.7 [27.2]63.0 [21.0].144CO peak, L/min7.4 [3.0]7.8 [3.2]6.4 [2.2].058Svo2 peak, %52.0 [9.8]52.6 [9.55]50.7 [10.4].341PVR peak, WU2.6 [1.7]2.2 [1.3]3.5 [2.1].013V˙O2 peak, mL/min482.8 [195.1]517.1 [202.3]402.2 [153.1].024Workload, W52.3 [21.8]53.9 [22.6]47.7 [18.9].242Data are presented as mean [SD] or as otherwise indicated. Items showing statistically significant differences were indicated in bold. APHR = age-predicted heart rate; CO = cardiac output; CRI = chronotropic response index; dPAP = diastolic pulmonary arterial pressure; HR = heart rate; mPAP = mean pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; PVR = pulmonary vascular resistance; RAP = right atrial pressure; sPAP = systolic pulmonary arterial pressure; Svo2 = mixed venous oxygen saturation; TAPSE = tricuspid annular plane systolic excursion; V˙O2 = maximum oxygen consumption; WU = Wood units. Exercise Right Heart Catheterization: Comparisons of HR Response and Hemodynamics Data are presented as mean [SD] or as otherwise indicated. Items showing statistically significant differences were indicated in bold. APHR = age-predicted heart rate; CO = cardiac output; CRI = chronotropic response index; dPAP = diastolic pulmonary arterial pressure; HR = heart rate; mPAP = mean pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; PVR = pulmonary vascular resistance; RAP = right atrial pressure; sPAP = systolic pulmonary arterial pressure; Svo2 = mixed venous oxygen saturation; TAPSE = tricuspid annular plane systolic excursion; V˙O2 = maximum oxygen consumption; WU = Wood units. A, B, CRI and delta HR/resting HR. The relationship between TAPSE/sPAP and chronotropic response in patients with pulmonary arterial hypertension associated with connective tissue disease. The chronotropic response, evaluated using the CRI and delta HR/resting HR, was significantly lower in the TAPSE/sPAP < 0.55 group. CRI = chronotropic response index; HR = heart rate; sPAP = systolic pulmonary arterial pressure; TAPSE = tricuspid annular plane systolic excursion. Exercise RHC At rest, the TAPSE/sPAP < 0.55 group showed higher HR, higher mean PAP (17.2 ± 4.2 vs 21.5 ± 7.1 mm Hg; P = .015), and higher PVR (1.9 ± 1.1 vs 3.6 ± 2.3 WU; P = .001). At peak exercise, the TAPSE/sPAP < 0.55 group had higher peak PVR (2.2 ± 1.3 vs 3.5 ± 2.1 WU; P = .013), lower systolic BP (198.9 ± 35.4 vs 173.7 ± 33.7 mm Hg; P = .016), and lower peak V˙o2 (517.1 ± 202.3 vs 402.2 ± 153.1 mL/min; P = .024) (Fig 4). Peak CO in the TAPSE/sPAP < 0.55 group was lower (7.8 ± 3.2 vs 6.4 ± 2.2 L/min; P = .058), but the difference was not significant. A, B, Pulmonary vascular resistance and peak V˙o2. The relationship between TAPSE/sPAP and exercise intolerance in patients with pulmonary arterial hypertension associated with connective tissue disease. The TAPSE/sPAP < 0.55 group had higher PVR and lower V˙o2 at peak. PVR = pulmonary vascular resistance; sPAP = systolic pulmonary arterial pressure; TAPSE = tricuspid annular plane systolic excursion; V˙o2 = maximum oxygen consumption. Discussion This study demonstrated the association between RV dysfunction and chronotropic response in patients with CTD-PAH, as assessed using exercise RHC. To evaluate the relationship between early RV dysfunction and chronotropic response, patients were divided into 2 groups based on the TAPSE/sPAP cutoff value of 0.55. The main results in this study revealed the following: (1) chronotropic incompetence was observed in 94% of patients with CTD-PAH; (2) RV dysfunction accompanied by CTD-PAH had no significant impact on the prevalence of chronotropic incompetence; and (3) patients with CTD-PAH with RV dysfunction had elevated resting HR and significantly lower values of chronotropic response, evaluated via the CRI and delta HR/resting HR. Our study suggests that RV dysfunction may be associated with worsening chronotropic response in patients with CTD-PAH. Although there was no significant difference in the prevalence of chronotropic incompetence, and the limited sample size may have affected the ability to detect significant differences in some parameters, the severity of chronotropic response impairment was significantly associated with RV dysfunction. The secondary outcomes regarding hemodynamic parameters were as follows. First, patients with CTD-PAH with impaired RV function had smaller LV chamber sizes and lower stroke volume at rest. Second, in patients with CTD-PAH with TAPSE/sPAP < 0.55, peak PAP was significantly higher and systolic BP was significantly lower during exercise; resting BP was comparable with that of the TAPSE/sPAP ≥ 0.55 group. Although peak CO during exercise was lower in patients with CTD-PAH with TAPSE/sPAP < 0.55, the difference was not statistically significant. Finally, patients with CTD-PAH with TAPSE/sPAP < 0.55 presented with higher PVR, and their peak V˙o2 was significantly lower. Collectively, these findings suggest that RV dysfunction in patients with CTD-PAH is associated with chronotropic incompetence, which may contribute to further reductions in exercise capacity. The findings of this study are summarized in Figure 5. Pathophysiological cascade linking RV dysfunction to chronotropic incompetence and exercise intolerance in patients with pulmonary arterial hypertension associated with connective tissue disease. The sequence begins with patients with connective tissue disease who have pulmonary arterial hypertension characterized by elevated PVR and impaired RV function (TAPSE/sPAP < 0.55). This leads to decreased RV-SV and Svo2, which reduces left ventricular preload and subsequently decreases CO. The diminished CO results in lower sBP and reduced peak V˙o2 during exercise. These hemodynamic abnormalities contribute to worsening chronotropic incompetence, manifested by reduced CRI and decreased delta HR relative to resting HR. This chronotropic dysfunction ultimately results in severe exercise intolerance. The gray box outlines the underlying physiological mechanisms: decreased sBP during exercise leads to reduced baroreflex sensitivity, which causes decreased sympathetic nervous system activity. This autonomic dysregulation disturbs the normal HR increase during exercise, creating a vicious cycle that perpetuates exercise intolerance. CO = cardiac output; CRI = chronotropic response index; HR = heart rate; PA = pulmonary arterial; PAH = pulmonary arterial hypertension; peak V˙o2 = peak oxygen consumption; PVR = pulmonary vascular resistance; RV = right ventricular; sBP = systolic BP; sPAP = systolic pulmonary arterial pressure; SV = stroke volume; Svo2 = mixed venous oxygen saturation; TAPSE = tricuspid annular plane systolic excursion. Previous clinical studies demonstrated that patients with PAH tended to have chronotropic incompetence.5, 6, 7 However, the mechanism underlying this pathology, particularly the association of RV function, remains poorly elucidated. The right side of the heart, designed for low-pressure and high-flow circulation, has limited reserve capacity against afterload elevation. RV function plays a critical role in maintaining preload to the left ventricle, not only at rest, but also during exercise. In patients with CTD-PAH, progressive increases in PVR and sustained elevations in RV afterload eventually lead to a decline in RV systolic function over time.22 The coexistence of elevated PVR and impaired RV function can result in further reductions in LV preload.24 A left ventricle receiving limited preload cannot fully use the Frank-Starling mechanism to generate sufficient stroke work.25 In fact, peak BP in the TAPSE/sPAP < 0.55 group was lower (Table 3). This RV-PA uncoupling may restrict peak CO during exercise in patients with PAH, thereby becoming a major determinant of exercise intolerance.22 Regarding RV-PA uncoupling, patients with PAH with more advanced RV dysfunction, defined as TAPSE/sPAP < 0.31, had increased mortality.26 Additionally, exercise capacity and survival deteriorated precipitously in patients with TAPSE/sPAP < 0.19.27 In the natural course of PAH, the progressive worsening of RV-PA uncoupling coincides with a marked reduction in exercise capacity.5, 6, 7 Both RV dysfunction and chronotropic incompetence—independently or synergistically—may clinically contribute to impaired exercise tolerance in patients with CTD-PAH. The attenuated rise in BP during exercise, which is associated with a reduced pulse pressure, may diminish baroreceptor input signaling from the carotid bodies and aortic arch, thereby impairing autonomic HR regulation.28,29 Additionally, sympathetic nervous system activation in PAH affects chronotropic response. Atrial septostomy for patients with severe PAH revealed a decrease in right atrial distension and lower muscle sympathetic nerve activity.30 It reflects the known phenomenon described by Bainbridge, where delta right atrial pressure and delta muscle sympathetic nerve activity correlated. Plasma neurohormone activities, such as norepinephrine, aldosterone, and renin, were not affected by atrial septostomy.30 We did not collect data on right atrial pressure and size during exercise and plasma neurohormone; therefore, we could not conduct a detailed examination of this point. Impaired CO and metabolic efficiency, evidenced by decreased peak V˙o2, may further exacerbate chronotropic incompetence through autonomic dysregulation and β-adrenergic receptor downregulation.9 Superimposing chronotropic incompetence on already impaired exercise tolerance in patients with PAH amplifies functional impairment. This study provides a circulatory physiological hypothesis explaining why RV dysfunction predisposes patients with CTD-PAH to chronotropic incompetence. Study Limitations This was a single-center, retrospective study with a limited sample size, restricting the ability to draw definitive conclusions regarding causality. Although reverse causality cannot be excluded, a plausible mechanism involves the combined effect of elevated PVR and RV impairment, which limits adequate LV preload during exercise. Post hoc power calculations showed a power of 0.61 for the CRI (calculated minimum power sample size: n = 52) and a power of 0.87 for delta HR/resting HR (calculated minimum power sample size: n = 28). The power for the CRI did not meet the ideal level of 0.8. The lack of a significant difference in CRI prevalence may be because of insufficient statistical power. We sincerely acknowledge the limitation of this study being a small-sample study; however, a significant difference was detected, that is, a large effect size was confirmed. The observed association between RV dysfunction and chronotropic incompetence may reflect diminished baroreceptor signaling. Systolic BP and systemic vascular resistance were measured; however, the direct assessment of autonomic nervous system function was not performed. Although theoretical physiological explanations can be proposed, prospective studies are required to confirm the explanations. In CTD-PAH, advanced disease stage and longer disease duration contribute to RV impairment; however, the precise temporal evolution remains unclear. Peak HR was measured during maximal exercise using the exercise RHC protocol with patients in a supine position, which may have led to earlier symptom limitation compared with upright exercise. However, all participants reached a Borg scale score ≥ 17, indicating they exercised near their symptom limit. Interpretation Chronotropic incompetence was highly prevalent in patients with CTD-PAH. Our findings demonstrate that patients with concomitant RV impairment had significantly worse chronotropic response than those with preserved RV function. This suggests that RV impairment, likely through restricted LV preload and blunted BP response during exercise, is associated with chronotropic incompetence, which further exacerbates exercise intolerance. Funding/Support The authors have reported to CHEST Pulmonary that no funding was received for this study. Financial/Nonfinancial Disclosures None declared. Acknowledgments Author contributions: Y. Nakamura and M. H. are responsible for all content in the manuscript. Y. Nakamura, M. H., K. S., and T. O. contributed to concept and design. Y. Nakamura and M. H. contributed to statistical analysis, drafting of the manuscript, and analysis and interpretation of data. T. S., N. N., M. M., T. M., K. H., M. T., M. N., and H. M. contributed to administrative, technical, and material support. M. H. and M. K. supervised the study. All authors performed critical revision of the manuscript for important intellectual content. Other contributions: We thank all participants in this study and all medical staff at The Second Department of Internal Medicine, Department of Cardiology and Nephrology, University of Occupational and Environmental Health, Japan. References